Roka Bioscience To Exhibit And Present At IPPE 2017 Poultry Expo

WARREN, N.J., Jan. 25, 2017 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens will be exhibiting and presenting at the International Production and Processing Expo. The convention will take place Jan 31-Feb 2 at the Georgia World Congress Center in Atlanta, Georgia. IPPE is the largest annual trade show for the poultry, meat and feed industries. Roka Bioscience will be exhibiting at booth B8168 and will also be presenting a TECH Talk on the topic of Effectiveness of Feed Interventions Strategies Thursday February 2^nd at 11 -11:20 am in C1305.

Lisa Leier-McHugh of Roka Bioscience and TJ Gaydos of Phileo-Lesaffre will be presenting the session titled: The Application of Rapid Turnaround of a Semi-quantitative Non-Culture Based Testing Method to Monitor the Effectiveness in Live Flock Feed Interventions.  The presentation  will describe the advantages to utilizing a rapid molecular quantitation method for salmonella to monitor the effectiveness feed intervention strategies in Live Flocks.

"Controlling and managing Salmonella is increasingly being pushed down the production chain into live growth environments. Rapidly measuring and monitoring Salmonella load as a risk indicator at flock harvest can be very useful data to convey to buyers," stated Lisa Leier-McHugh Business Development Manager, Roka Bioscience. 

"When selecting a testing modality for any pathogen it is important to consider accuracy, precision, cost effectiveness, and turn-around time. The faster you have a reliable result, the faster you can make an informed decision," stated TJ Gaydos DVM, MAM, DACPV Poultry Technical Service Manager, Phileo Lesaffre Animal Care. For more information about Phileo Lesaffre visit www.lesaffre.com

For more information, visit the Roka booth during the show. You may also request a copy of the presentation by visiting our IPPE Tech Talk Page. 

Phileo Lesaffre Animal Care

Phileo Backed by 30 years of experience and a global staff of 130 people, Phileo is viewed as a major player on the animal nutrition, health and welfare market. Working at the crossroads of nutrition and animal health, Phileo designs, develops and delivers innovative nutritional solutions to enhance animal health and performance. Our innovative capacity and mastery of manufacturing processes enable us to meet the most stringent demands of industry and livestock production. Thanks to our global presence, we aim to stay close to our customers and able to adapt readily to their needs.

Roka Bioscience 

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  

For more information about Roka Bioscience and its Salmonella enterica detection assays please visit www.rokabio.com and connect with us on LinkedIn, twitter and Facebook.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the "Exchange Act"). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we "believe", "expect", "anticipate", "plan" and similar expressions) that are not statements of historical fact should be considered forward-looking statements and should be read in conjunction with the Condensed Financial Statements  included in this press release and the discussion below. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Investor Contact:
Roka Bioscience, Inc.
[email protected]
855-ROKABIO (855-765-2246)

SOURCE Roka Bioscience, Inc.

Related Links

http://www.rokabio.com